The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
A new framework for advancing in drug‐induced liver injury research. The Prospective European DILI Registry
Abstract
Background & Aims: No multi‐national prospective study of drug‐induced liver injury (DILI) has originated in Europe. The design of a prospective European DILI registry, clinical features and short‐term outcomes of the cases and controls is reported. Methods: Patients with suspected DILI were prospectively enrolled in the United Kingdom, Spain, Germany, Switzerland, Portugal and Iceland, 2016–2021. DILI cases or non‐DILI acute liver injury controls following causality assessment were enrolled. Results: Of 446 adjudicated patients, 246 DILI patients and 100 had acute liver injury due to other aetiologies, mostly autoimmune hepatitis ( n = 42) and viral hepatitis ( n = 34). DILI patients (mean age 56 years), 57% women, 60% with jaundice and 3.6% had pre‐existing liver disease. DILI cases and non‐DILI acute liver injury controls had similar demographics, clinical features and outcomes. A single agent was implicated in 199 (81%) DILI cases. Amoxicillin‐clavulanate, flucloxacillin, atorvastatin, nivolumab/ipilimumab, infliximab and nitrofurantoin were the most commonly implicated drugs. Multiple conventional medications were implicated in 37 (15%) and 18 cases were caused by herbal and dietary supplements. The most common single causative drug classes were antibacterials (40%) and antineoplastic/immunomodulating agents (27%). Overall, 13 (5.3%) had drug‐induced autoimmune‐like hepatitis due to nitrofurantoin, methyldopa, infliximab, methylprednisolone and minocycline. Only six (2.4%) DILI patients died (50% had liver‐related death), and another six received liver transplantation. Conclusions: In this first multi‐national European prospective DILI Registry study, antibacterials were the most commonly implicated medications, whereas antineoplastic and immunomodulating agents accounted for higher proportion of DILI than previously described. This European initiative provides an important opportunity to advance the study on DILI.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Expert judgement is the approach used to assess causality in large prospective DILI registries such as the Spanish, Latin American, European, and DILIN registries.
“Expert judgement is the approach used to assess causality in large prospective DILI registries such as the Spanish, the Latin American, the European, or the DILIN.”
From Methods for causality assessment of idiosyncratic drug‐induced liver injury (2025) · cites this paper as [9]
In response to limitations of expert judgement, the Spanish, LATINDILI and Pro-Euro DILI networks combined evaluation of suspected DILI cases by three experts with further assessment using causality scales, while DILIN developed a structured expert opinion process.
“In response to these limitations, the Spanish, LATINDILI and Pro‐Euro DILI networks have combined the evaluation of suspected DILI cases by three experts and further assessment using causality scales, while the DILIN has developed a structured expert opinion process.”
From Methods for causality assessment of idiosyncratic drug‐induced liver injury (2025) · cites this paper as [9]
The pharmacological groups most frequently involved in DILI are antimicrobials, cardiovascular system drugs, and musculoskeletal system drugs, although this varies according to country and areas of the world.
“The pharmacological groups most frequently involved in DILI are antimicrobials, cardiovascular system drugs, and musculoskeletal system drugs, although this varies according to country and areas of the world [3][4][5][6].”
From DILI Differences and Similarities between the US and Europe (2026) · cites this paper as [5]
ChILI is accounting for an increasing proportion of recent DILI cohort studies.
“Checkpoint inhibitor-induced liver injury (ChILI) is accounting for an increasing proportion of recent DILI cohort studies.”
From Nomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis (DI-ALH): An expert opinion meeting report (2023) · cites this paper as [10]
There are differences between the main agents responsible in the three registries analysed.
“It is important to note that there are differences between the main agents responsible in the three registries analysed (Table 1; Fig. 1) [3][4][5].”
From DILI Differences and Similarities between the US and Europe (2026) · cites this paper as [5]
In the more recent European registry, there is a notable increase in the presence of flucoxacillin (11%), atorvastatin (8%), and nivolumab-ipilimumab, a combination with 16 cases (8%).
“In contrast, in the more recent European registry, there is a notable increase in the presence of flucoxacillin (11%), atorvastatin (8%), and nivolumab-ipilimumab, a combination with 16 cases (8%) [5].”
From DILI Differences and Similarities between the US and Europe (2026) · cites this paper as [5]
In the Spanish register there is a predominance of males, compared to the other two where females predominate (48% in Spanish, 57% in European and 59% in American).
“Furthermore, in the Spanish register there is a predominance of males, compared to the other two where females predominate (48% in Spanish, 57% in European and 59% in American) [3][4][5].”
From DILI Differences and Similarities between the US and Europe (2026) · cites this paper as [5]
Data on liver transplantation are higher in the American DILI cohort (4%) than in the European (2.5%) and Spanish (1.5%) cohorts.
“Data on liver transplantation are also higher in the American DILI cohort (4%) than in the European (2.5%) and Spanish (1.5%) cohorts [3][4][5].”
From DILI Differences and Similarities between the US and Europe (2026) · cites this paper as [5]
In all three registries, the predominant pattern was hepatocellular, with jaundice rates of between 60 and 70%.
“In all three registries, the predominant pattern was hepatocellular, with jaundice rates of between 60 and 70% [3][4][5].”
From DILI Differences and Similarities between the US and Europe (2026) · cites this paper as [5]
The average age was around 55 years in both the European and Spanish hepatotoxicity registries, being slightly lower (49 years on average) in the North American registry.
“Regarding to demographic data, it should be noted that the average age was around 55 years in both the European and Spanish hepatotoxicity registries, being slightly lower (49 years on average) in the North American registry.”
From DILI Differences and Similarities between the US and Europe (2026) · cites this paper as [5]
In terms of severity of liver injury, percentages are fairly homogeneous between the Spanish and European registries, with a higher frequency of severe and fatal outcomes in the American registry, at 19% and 7% respectively.
“In terms of severity of liver injury, percentages are fairly homogeneous between the Spanish and European registries, with a higher frequency of severe and fatal outcomes in the American registry, at 19% and 7% respectively.”
From DILI Differences and Similarities between the US and Europe (2026) · cites this paper as [5]
Amoxicillin-clavulanic acid is the most common xenobiotic, accounting for 10.1%, 22.9% and 12% in American, Spanish and European registries, respectively.
“Evaluating only the responsible agents separately, amoxicillin-clavulanic acid is the most common xenobiotic, accounting for 10.1%, 22.9% and 12% in American, Spanish and European registries, respectively [3][4][5].”
From DILI Differences and Similarities between the US and Europe (2026) · cites this paper as [5]
Regarding herbal products, the percentage is much higher in the American registry (145 cases, 16%) than in the Spanish and European registries (6% in both, including cases of anabolic steroids).
“Regarding to herbal products, the percentage is much higher in the American registry (145 cases, 16%) than in the Spanish and European registries (6% in both, including cases of anabolic steroids) [3][4][5]”
From DILI Differences and Similarities between the US and Europe (2026) · cites this paper as [5]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
EASL Clinical Practice Guidelines: Drug-induced liver injury
Andrade, R. J., Aithal, G. P., Björnsson, E. S., Kaplowitz, N., Kullak-Ublick, G. A., Larrey, D., & Karlsen, T. H. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.02.014 · Cited by 1,276
Self-citationAndrade, R. J., Chalasani, N., Björnsson, E. S., Suzuki, A., Kullak-Ublick, G. A., Watkins, P. B., Devarbhavi, H., Merz, M., Lucena, M. I., Kaplowitz, N., et al. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0105-0 · Cited by 924
Self-citationBjörnsson, E. S., Bergmann, O. M., Björnsson, H. K., Kvaran, R. B., & Olafsson, S. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.02.006 · Cited by 865
Incidence and Etiology of Drug-Induced Liver Injury in Mainland China
Shen, T., Liu, Y., Shang, J., Xie, Q., Li, J., Yan, M., Xu, J., Niu, J., Liu, J., Watkins, P. B., et al. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.02.002 · Cited by 615
Self-citationACG Clinical Guideline: Diagnosis and Management of Idiosyncratic Drug-Induced Liver Injury
Chalasani, N. P., Maddur, H., Russo, M. W., Wong, R. J., Reddy, K. R., & on behalf of the Practice Parameters Committee of the American College of Gastroenterology (2021) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000001259 · Cited by 430
A revised electronic version of RUCAM for the diagnosis of DILI
Hayashi, P. H., Lucena, M. I., Fontana, R. J., Bjornsson, E. S., Aithal, G. P., Barnhart, H., Gonzalez‐Jimenez, A., Yang, Q., Gu, J., Andrade, R. J., et al. (2022) · Hepatology · doi:10.1002/hep.32327 · Cited by 160
Self-citationBiologic and checkpoint inhibitor‐induced liver injury: a systematic literature review
Shah, P., Sundaram, V., & Björnsson, E. (2020) · Hepatology Communications · doi:10.1002/hep4.1465 · Cited by 64
Flagged first, then by citations
Research works printed but not linked: 36
- 10.1016/j.dld.2005.06.004 · DOI
- 10.1016/j.jhep.2021.01.029 · DOI
- 10.1002/hep.20800 · DOI · Paper page
- 10.1097/MEG.0000000000002272 · DOI
- 10.1053/j.gastro.2015.03.006 · DOI · Paper page
- 10.1016/j.jceh.2020.11.002 · DOI
- 10.1038/ajg.2012.138 · DOI
- 10.1016/S0140-6736(21)01701-3 · DOI · Paper page
- 10.1038/clpt.2011.58 · DOI
- 10.1053/j.gastro.2014.03.050 · DOI · Paper page
- 10.1016/0895-4356(93)90101-6 · DOI · Paper page
- 10.1038/ajg.2015.283 · DOI
- Chijioke O, 2015, Hepatitis E virus detection in liver tissue from patients with suspected drug‐induced liver injury, Front Med (Lausanne), 2, 20
- 10.1111/liv.14713 · DOI
- 10.3389/fmicb.2021.737486 · DOI
- 10.1053/j.gastro.2008.09.011 · DOI
- 10.1016/j.jhep.2018.01.033 · DOI · Paper page
- 10.1111/liv.13746 · DOI · Paper page
- 10.14309/ajg.0000000000000398 · DOI
- 10.1002/hep.28323 · DOI · Paper page
- 10.1016/j.cgh.2012.12.025 · DOI
- 10.1016/j.cgh.2014.07.062 · DOI · Paper page
- 10.1016/j.jhep.2021.08.024 · DOI · Paper page
- 10.1111/j.1365-2125.2004.02133.x · DOI
- 10.1111/bcp.14254 · DOI
- 10.1111/bcp.14294 · DOI
- 10.1007/s40264-021-01049-z · DOI
- 10.1016/j.jhep.2011.07.023 · DOI
- 10.1371/journal.pone.0151587 · DOI
- 10.4414/smw.2021.20503 · DOI · Paper page
- 10.1002/hep.23588 · DOI · Paper page
- 10.1016/j.cgh.2016.05.043 · DOI · Paper page
- 10.3389/fphar.2021.744488 · DOI
- 10.3389/fphar.2022.876868 · DOI
- 10.3389/fphar.2022.820724 · DOI
- 10.1016/j.phrs.2020.105404 · DOI · Paper page
Cited by
Sorted by citations
Andrade, R. J., Aithal, G. P., de Boer, Y. S., Liberal, R., Gerbes, A., Regev, A., Terziroli Beretta-Piccoli, B., Schramm, C., Kleiner, D. E., De Martin, E., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.04.033 · Cited by 166
Self-citationMethods for causality assessment of idiosyncratic drug‐induced liver injury
García‐Cortés, M., Matilla‐Cabello, G., & Lucena, M. I. (2025) · Liver International · doi:10.1111/liv.16083 · Cited by 15
Self-citationThe contemporary epidemiology, causes, and management of drug-induced liver injury
Swanson, L., & Fontana, R. J. (2026) · Hepatology Communications · doi:10.1097/hc9.0000000000001011
DILI Differences and Similarities between the US and Europe
Toro-Ortiz, J. P., Andrade, R. J., & Pinazo-Bandera, J. (2026) · Current Hepatology Reports · doi:10.1007/s11901-026-00733-x
Self-citation
Metadata
- Authors
- Björnsson, E. S., Stephens, C., Atallah, E., Robles‐Diaz, M., Alvarez‐Alvarez, I., Gerbes, A., Weber, S., Stirnimann, G., Kullak‐Ublick, G., Cortez‐Pinto, H., Grove, J. I., Lucena, M. I., Andrade, R. J., & Aithal, G. P.
- Affiliations
- Faculty of Medicine University of Iceland Reykjavík Iceland
- Servicios de Aparato Digestivo y Farmacología Clínica Hospital Universitario Virgen de la Victoria, Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina‐IBIMA Plataforma BIONAND, Universidad de Málaga Málaga Spain
- Nottingham Digestive Diseases Centre, Translational Medical Sciences, School of Medicine University of Nottingham Nottingham UK
- Department of Medicine II LMU Klinikum Munich Munich Germany
- Department of Visceral Surgery and Medicine Inselspital University Hospital and University of Bern Bern Switzerland
- Department of Clinical Pharmacology and Toxicology University Hospital Zurich, University of Zurich Zurich Switzerland
- Clínica Universitária de Gastrenterologia, Faculdade de Medicina de Lisboa Universidade de Lisboa, Centro Hospitalar Lisboa Norte, HSM Lisbon Portugal
- ORCID
- Venue
- Liver International
- Publisher
- Wiley
- Published
- 2022-08-15
- Volume
- 43
- Issue
- 1
- Pages
- 115-126
- ISSN
- 1478-3223
- 1478-3231
- PMC
- PMC7614006
- Cited by
- 69
- References
- 7
- Language
- en
- Funders
- Agencia Española de Medicamentos y Productos Sanitarios
- Instituto de Salud Carlos III
- European Cooperation in Science and Technology
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review